Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: absent (23), missing (300), gone (960)

Finance and Performance Reports 2023-24 Month 2 May 2023

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Finance Report 2023-24 Month 2
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-2-May-2023.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

DOC CRF User Guidelines

Description: SCBR University Hospital Southampton NHS Foundation Trust GUIDELINES FOR USERS OF THE SOUTHAMPTON NIHR CLINICAL RESEARCH FACILITY (CRF) Welc
Url: /Media/Southampton-Clinical-Research/BRC-CRF-templates/DOC-CRF-User-Guidelines.pdf

Engaging for increased research participation - full report

Description: Engaging for increased research participation Public and healthcare professionals' perceptions For further information
Url: /Media/Southampton-Clinical-Research/Marketresearch/Engaging-for-increased-research-participation-full-report-v2.pdf

People who refuse medical or surgical treatment for self inflicted injury

Description: Auto Generated Title On these pages I discuss the clinical law on which our nursing and medical staff rely when caring for our patients.
Url: /HealthProfessionals/Clinical-law-updates/People-who-refuse-medical-or-surgical-treatment-for-self-inflicted-injury.aspx

Health and safety policy

Description: Health and Safety Policy Date Issued: 21/11/18 Review Date: 21/11/21 Document Type: Policy Version: 10.0 Contents Paragraph 1 2 3
Url: /Media/UHS-website-2019/Docs/Policies/Health-and-safety-policy.pdf

Papers Council of Governors 19 October 2022

Description: Agenda attachments 1 CoG Agenda - 19.10.2022.docx Date Time Location Chair Agenda Council of Governors 1
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-19-October-2022.pdf

Ipilimumab Ver 1

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authorisation, as an option for treating adults with previously
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf

Flow and residual study (bladder test) - patient information

Description: This factsheet explains what to expect at your flow and residual study test appointment.
Url: /Media/UHS-website-2019/Patientinformation/Womenshealth/Flow-and-residual-study-bladder-test-3002-PIL.pdf

Cemiplimab

Description: Chemotherapy Protocol SKIN CANCER Cemiplimab (350mg) Regimen  Skin – Cemiplimab (350mg) Indication  Metastatic or locally advanced cutaneous squamous cell carcinoma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Cemiplimab.pdf

71 to 80 of 413

Previous … 6 7 8 9 10 … Next